Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841499 · ClinicalTrials.gov registry record · NA
Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause
A NA study, sponsored by University of South Alabama.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT04841499: Completed NA study, sponsored by University of South Alabama.
NCT04841499 is a NA study that has completed, run by University of South Alabama. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841499, a NA study, has completed, sponsored by University of South Alabama.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a short supplementation (7days) with BASIS™ increases the natural production of estradiol, measured in urinary waste. The overall objective is to determine whether through increased estradiol levels, the undesirable menopausal effects, assessed via questionnaires, are mitigated by a short-term supplementation with BASIS™
Interventions
- DRUG BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-04-05 |
| Est. Completion | 2021-07-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04841499
The ClinicalTrials.gov registry entry for NCT04841499 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Alabama, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg) is the first listed.
NCT04841499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04841499 about?
NCT04841499 is a clinical study titled "Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause". The purpose of this study is to determine whether a short supplementation (7days) with BASIS™ increases the natural production of estradiol, measured in urinary waste. The overall objective is to determine whether through increased estradiol levels, the undesirable menopausal effects, assessed via q...
What is the current status of trial NCT04841499?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-04-05. Estimated completion is 2021-07-15.
What interventions are being tested in trial NCT04841499?
The interventions under investigation include: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg) (DRUG).
Who is sponsoring clinical trial NCT04841499?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.